Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

Simonetta Viviani, MD, Francesco Spina, MD, Arabella Mazzocchi, Maria Galbiati, Flavio Crippa, MD, Lucia Farina, MD PhD, Anna Guidetti, MD, Massimo Di Nicola, Liliana Franca Devizzi, MD, Paola Matteucci, MD, Michele Magni, MD, Anna Dodero, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2016) 128 (22): 3009.

https://doi.org/10.1182/blood.V128.22.3009.3009

Published: 2016

Journal Articles

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma

Roberta Zappasodi, Giusi Ruggiero, Carla Guarnotta, Monica Tortoreto, Cristina Tringali, Alessandra Cavanè, Antonello D. Cabras, Lorenzo Castagnoli, Bruno Venerando, Nadia Zaffaroni, Alessandro M. Gianni, Filippo De Braud, Claudio Tripodo, Serenella M. Pupa, Massimo Di Nicola

Blood (2015) 125 (11): 1768–1771.

https://doi.org/10.1182/blood-2014-07-590034

Published: 2015

Includes: Supplemental data

Journal Articles

Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

Anna Guidetti, MD, Simonetta Viviani, MD, Anna Dodero, MD, Lucia Farina, MD, Domenico Russo, MD PhD, Pietro Bulian, Massimo Di Nicola, MD, Arabella Mazzocchi, MD, Fernando Ravagnani, MD, Paolo Corradini, MD, Alessandro Massimo Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2014) 124 (21): 4459.

https://doi.org/10.1182/blood.V124.21.4459.4459

Published: 2014

Journal Articles

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

Simonetta Viviani, MD, Serena Dalto, MD, Paola Matteucci, MD, Massimo Di Nicola, MD, Anna Guidetti, MD, Liliana Devizzi, MD, Michele Magni, MD, Anna Dodero, MD, Lucia Farina, MD, Francesco Spina, MD, Alessandro M. Gianni, MD, Paolo Corradini, MD

Blood (2014) 124 (21): 5428.

https://doi.org/10.1182/blood.V124.21.5428.5428

Published: 2014

Journal Articles

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

Andrés J.M. Ferreri, Giovanni Donadoni, MD, Maria Giuseppina Cabras, MD, Caterina Patti, MD, Michael Mian, Renato Zambello, MD, Corrado Tarella, MD, Massimo Di Nicola, MD, Alfonso D'Arco, Gianluca Doa, Marta Bruno-Ventre, Marco Foppoli, MD, Alessandro Fanni, MD, Antonino Mulè, MD, Fabio Ciceri, MD, Federico Caligaris-Cappio, MD

Blood (2014) 124 (21): 1724.

https://doi.org/10.1182/blood.V124.21.1724.1724

Published: 2014

Journal Articles

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

Jacopo Mariotti, MD, Anna Guidetti, MD, Michele Magni, MD, Paola Matteucci, MD, Liliana Devizzi, MD, Andrés J.M. Ferreri, Paolo Corradini, MD, Anna Dodero, MD, Amalia De Renzo, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2014) 124 (21): 1734.

https://doi.org/10.1182/blood.V124.21.1734.1734

Published: 2014

Journal Articles

HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma

Roberta Zappasodi, PhD, Alessandra Cavanè, Monica Tortoreto, Cristina Tringali, Giusi Ruggiero, Lorenzo Castagnoli, Bruno Venerando, Nadia Zaffaroni, Serenella M Pupa, Alessandro Massimo Gianni, MD, Massimo Di Nicola, MD

Blood (2012) 120 (21): 1562.

https://doi.org/10.1182/blood.V120.21.1562.1562

Published: 2012

Journal Articles

Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)

Blood (2012) 120 (21): 746.

https://doi.org/10.1182/blood.V120.21.746.746

Published: 2012

Journal Articles

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

Anna Guidetti, MD, Simonetta Viviani, MD, Alfonso Marchianò, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Silvia L Locatelli, PhD, Domenico Russo, Pietro Bulian, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Laura Giordano, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2012) 120 (21): 3679.

https://doi.org/10.1182/blood.V120.21.3679.3679

Published: 2012

Journal Articles

MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma

Roberta Zappasodi, PhD, Alessandra Cavanè, Marilena V Iorio, Monica Tortoreto, Giusi Ruggiero, Michele Magni, MD, Carmelo Carlo-Stella, MD, Elda Tagliabue, Franco Zunino, Carlo M. Croce, MD, Alessandro M. Gianni, MD, Massimo Di Nicola, MD

Blood (2011) 118 (21): 2729.

https://doi.org/10.1182/blood.V118.21.2729.2729

Published: 2011

Journal Articles

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Marco Ruella, MD, Andrea Filippi, MD, Anna DI Russo, MD, Daniele Caracciolo, MD, Paola Matteucci, MD, Michele Magni, MD, Massimo Di Nicola, MD, Umberto Ricardi, MD, Vittorio Montefusco, MD, Guido Parvis, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD, Liliana Devizzi, MD

Blood (2011) 118 (21): 3699.

https://doi.org/10.1182/blood.V118.21.3699.3699

Published: 2011

Journal Articles

Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

Anna Guidetti, MD, Silvia Locatelli, PhD, Simonetta Viviani, MD, Anna Dodero, MD, Lucia Farina, MD, PhD, Domenico Russo, Pietro Bulian, Roberto Sorasio, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Andrea Anichini, PhD, Alessandro M. Gianni, MD, Carmelo Carlo-Stella, MD

Blood (2011) 118 (21): 3705.

https://doi.org/10.1182/blood.V118.21.3705.3705

Published: 2011

Journal Articles

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Blood (2011) 118 (21): 1647.

https://doi.org/10.1182/blood.V118.21.1647.1647

Published: 2011

Journal Articles

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

Silvia Locatelli, PhD, Arianna Giacomini, PhD, Anna Guidetti, MD, Loredana Cleris, PhD, Michele Magni, MD, Massimo Di Nicola, MD, Roberta Mortarini, PhD, Alessandro M Gianni, MD, Andrea Anichini, PhD, Carmelo Carlo-Stella, MD

Blood (2011) 118 (21): 1653.

https://doi.org/10.1182/blood.V118.21.1653.1653

Published: 2011

Journal Articles

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target

Roberta Zappasodi, Italia Bongarzone, Gaia C. Ghedini, Lorenzo Castagnoli, Antonello D. Cabras, Antonella Messina, Monica Tortoreto, Claudio Tripodo, Michele Magni, Carmelo Carlo-Stella, Alessandro M. Gianni, Serenella M. Pupa, Massimo Di Nicola

Blood (2011) 118 (16): 4421–4430.

https://doi.org/10.1182/blood-2011-06-364570

Published: 2011

Includes: Supplemental data

Journal Articles

Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial

Carmelo Carlo-Stella, MD, Anna Guidetti, MD, Simonetta Viviani, MD, Liliana Devizzi, MD, Paola Matteucci, MD, Alfonso Marchianò, MD, Rodolfo Lanocita, MD, Stefania Zambelli, MD, Roberto Sorasio, MD, Massimo Di Nicola, MD, Paolo Corradini, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 2861.

https://doi.org/10.1182/blood.V116.21.2861.2861

Published: 2010

Journal Articles

Serological Identification of HSP105 as a Novel Non-Hodgkin Lymphoma Therapeutic Target

Roberta Zappasodi, Gaia C Ghedini, Italia Bongarzone, Lorenzo Castagnoli, Maida de Bortoli, Piera Aiello, Alessandra Cavanè, Antonello D Cabras, Carmelo Carlo-Stella, Alessandro M. Gianni, MD, Serenella M Pupa, Massimo Di Nicola, MD

Blood (2010) 116 (21): 463.

https://doi.org/10.1182/blood.V116.21.463.463

Published: 2010

Journal Articles

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Anna Guidetti, MD, Carmelo Carlo-Stella, MD, Marco Ruella, MD, Rosalba Miceli, MD, Liliana Devizzi, MD, Daniela Sia, PhD, Silvia Locatelli, PhD, Arianna Giacomini, PhD, Michele Magni, MD, Paola Matteucci, MD, Stefano Buttiglieri, PhD, Alessandra Risso, PhD, Luigi Mariani, MD, Roberto Passera, PhD, Massimo Di Nicola, MD, Corrado Tarella, MD, Alessandro M. Gianni, MD

Blood (2010) 116 (21): 1289.

https://doi.org/10.1182/blood.V116.21.1289.1289

Published: 2010

Journal Articles

Human CD34 + cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature

Cristiana Lavazza, Carmelo Carlo-Stella, Arianna Giacomini, Loredana Cleris, Marco Righi, Daniela Sia, Massimo Di Nicola, Michele Magni, Paolo Longoni, Marco Milanesi, Maura Francolini, Annunziata Gloghini, Antonino Carbone, Franca Formelli, Alessandro M. Gianni

Blood (2010) 115 (11): 2231–2240.

https://doi.org/10.1182/blood-2009-08-239632

Published: 2010

Includes: Supplemental data

Journal Articles

High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.

Blood (2009) 114 (22): 1220.

https://doi.org/10.1182/blood.V114.22.1220.1220

Published: 2009

NARROW

TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy

HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma

Decrease of Serum TARC Levels As Predictive Biomarkers of Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients

Brentuximab Vedotin (BV) an Effective Treatment for Autologous (ASCT) and/or Allogeneic (alloSCT) Transplant naïve Patients with Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL) : A retrospective Single-Institution Study

High Doses of Antimetabolites Followed By High-Dose Sequential Chemoimmunotherapy and Autologous Stem Cell Transplant in Patients with Systemic B-Cell Lymphoma and Secondary Central Nervous System Involvement: Final Results of a Multicenter Phase II Trial

High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma

HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma

Chemoimmunotherapy with R-CHOP or High Dose Sequential Therapy with Autologous Stem Cell Transplantation (R-HDS) for High Risk Diffuse Large B-Cell Lymphomas Patients: Results of the Randomized R-HDS0305 Trial by Gruppo Italiano Terapie Innovative Nei Linfomi (GITIL)

Dual Targeted Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Patients with Relapsed/Refractory Lymphomas: Final Results of a Phase II Trial

MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma

Rituximab Followed by Involved Fields Radiotherapy (IF-RT) in Stage I-II Follicular Lymphoma (FL): Long Term Results,

Phosphorylation Levels of Extracellular-Signal Regulated Kinase (ERK) and AKT in Circulating Lymphocytes Predict Response to Targeted Therapy with Kinase Inhibitors in Refractory/Relapsed Hodgkin Lymphoma Patients,

Safety, Tolerability and Activity of Ofatumumab, Bendamustine and Dexamethasone Combination As First-Line Treatment of Mantle-Cell Lymphoma in the Elderly: A Multicenter Study

Preclinical Rationale for the Use of the Combined Treatment with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib in Hodgkin Lymphoma

Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target

Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas: Preliminary Results of a Phase II Trial

Serological Identification of HSP105 as a Novel Non-Hodgkin Lymphoma Therapeutic Target

The Risk of Secondary Myelodysplastic Syndrome/Acute Leukemia Following High-Dose Yttrium-90 Ibritumomab Tiuxetan Is Analogous to That Observed Following High-Dose Chemotherapy: a Matched-Pair Analysis In Non-Hodgkin Lymphoma Patients.

Human CD34 + cells engineered to express membrane-bound tumor necrosis factor–related apoptosis-inducing ligand target both tumor cells and tumor vasculature

High Response Rate with Favorable Survival Projections in High-Risk Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving R-CHOP-14 or Early Intensified Chemotherapy with Rituximab and Autograft (R-HDS): Results of the Interim Analysis of A GITIL Prospective Multicenter Phase III Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only